

Amendments to the Specification:

Please replace the paragraph (or section) beginning at page 10, line 1, with the following redlined paragraph (or section):

Figure 8 illustrates the results of epitope mapping studies on P501S. The peptides used in the study are shown from left to right at the bottom of the figure, as follows: MDRLVQRP GTRAVY LASVA (SEQ ID NO: 489), YLASVA AAFPVAAGATCLSHS (SEQ ID NO: 490), TCLSHSVAVVTASAALTGFT (SEQ ID NO: 491), ALTGFTFSALQILPYTLASL (SEQ ID NO: 492), YTLASLYHREKQVFLPKYRG (SEQ ID NO: 493), LPKYRGDTGGASSED¹SLM¹IS (SEQ ID NO: 494), DSLM¹ISFLPGPKPGAPFPNG (SEQ ID NO: 495), APFPNGHVGAGGSGLLP¹PPPA (SEQ ID NO: 496), LLP¹PPPALCGASACDVSVRV (SEQ ID NO: 497), DVSVRVVVGEPT¹EARVVPGR (SEQ ID NO: 498), RVVPGRGICLDLAILDSAFL (SEQ ID NO: 499), LDSAFLLSQVAPSLFMGSIV (SEQ ID NO: 500), FMGSIVQLSQSVTAYMVSAA (SEQ ID NO: 501).

Please replace the paragraph (or section) beginning at page 10, line 2, with the following redlined paragraph (or section):

Figure 9 is a schematic representation of the P501S protein (SEQ ID NO: 113) showing the location of transmembrane domains and predicted intracellular and extracellular domains.

Please replace the paragraph (or section) beginning at page 10, line 7, with the following redlined paragraph (or section):

Figure 11 shows the results of an ELISA assay to determine the specificity of rabbit polyclonal antisera raised against P501S. The depicted sequence corresponding to peptide P501S 306-320 is set forth in SEQ ID NO: 519 and the sequence corresponding to P501S 296-320 is set forth in SEQ ID NO: 520.